Tyra Biosciences Inc

NASDAQ TYRA

Data sourced from

and

Daily

Download Data

Tyra Biosciences Inc Price to Sales Ratio (P/S) on June 03, 2024: 1,687.13

Tyra Biosciences Inc Price to Sales Ratio (P/S) is 1,687.13 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Tyra Biosciences Inc 52-week high Price to Sales Ratio (P/S) is 1,996.54 on May 16, 2024, which is 18.34% above the current Price to Sales Ratio (P/S).
Tyra Biosciences Inc 52-week low Price to Sales Ratio (P/S) is 1,646.36 on May 30, 2024, which is -2.42% below the current Price to Sales Ratio (P/S).
Tyra Biosciences Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 1,835.28.

NASDAQ: TYRA

Tyra Biosciences Inc

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street, Carlsbad, CA, United States, 92008
Employees	49
Sector	Healthcare
Industry	Biotechnology

Description

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Key trends